

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3927462

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
PENG LI	06/20/2013
LAWRENCE P. WENNOGLE	06/20/2013
ROBERT DAVIS	06/20/2013
GRAHAM BUCKTON	06/20/2013
MARK HOOPER	06/20/2013
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	INTRA-CELLULAR THERAPIES, INC.
<b>Street Address:</b>	430 EAST 29TH STREET
<b>Internal Address:</b>	SUITE 900
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10016
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14409988
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	file@hoxpat.com
<b>Correspondent Name:</b>	HOXIE & ASSOCIATES, LLC
<b>Address Line 1:</b>	75 MAIN STREET
<b>Address Line 2:</b>	SUITE 203
<b>Address Line 4:</b>	MILLBURN, NEW JERSEY 07041
<b>ATTORNEY DOCKET NUMBER:</b>	IT-66-US
<b>NAME OF SUBMITTER:</b>	BRIAN W. STEGMAN
<b>SIGNATURE:</b>	/Brian W. Stegman/
<b>DATE SIGNED:</b>	06/21/2016
<b>Total Attachments: 15</b>	

source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page1.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page2.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page3.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page4.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page5.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page6.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page7.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page8.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page9.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page10.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page11.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page12.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page13.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page14.tif  
source=IT-66-PCT\_Executed Assignments\_Inventors to ITI#page15.tif

ASSIGNMENT

WHEREAS,

1. *Graham Buckton* residing at \_\_\_\_\_
  2. *Mark Hooper* residing at 4 HURSTLANE FREELAND WITNEY OXON UK
- hereinafter referred to as Assignor(s), have invented a certain invention entitled:

SALT CRYSTALS

for which invention an application (provisional or non-provisional) for a PCT patent was filed on June 21, 2013, under PCT Application No. PCT/US2013/047123, and

WHEREAS, Intra-Cellular Therapies, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware, and having an office and place of business at 3960 Broadway, New York, NY 10032, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Pursuant to the agreement PMSQ1105 with an Issue Date of June 19, 2009; PMS1170 with an Issue Date of August 24, 2009; and PMSQ1225 with an Issue Date of December 10, 2009, between Pharmaterials Limited, having a place of business at Unit B, 5 Boulton Road, Reading, RG2 0NH, United Kingdom, and Intra-Cellular Therapies, Inc., having a place of business at 3960 Broadway, New York, NY 10032, Assignor(s) assign and transfer to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, utility model applications, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, and the patents that may issue thereon,

Assignor(s) convey to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor(s) will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor(s) will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor(s) and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor(s) authorize Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor(s) and Assignee agree that New York State law governs this assignment, and

Assignee acknowledges and accepts this assignment, as evidenced by the signature of an officer or authorized representative of Assignee below.

IN WITNESS WHEREOF, Assignor has hereunto set their hand as indicated below.

This Assignment is effective as of: June 20, 2013

\_\_\_\_\_  
Assignor Mark Hooper  
\_\_\_\_\_  
Witness 18/6/14  
\_\_\_\_\_  
Witness 18/6/14

RUSSEL GOLDSMITH  
GARY MUDDOYMAN

\_\_\_\_\_  
Assignor Graham Buckton  
\_\_\_\_\_  
Witness  
\_\_\_\_\_

Witness

=====

Receipt acknowledged by Assignee:

\_\_\_\_\_  
Name: ~~Sharon Mates Allen Fienberg~~  
Title: ~~Chairman and Chief Executive Officer~~ Vice President, Business Development  
of Intra-Cellular Therapies, Inc.

Officer of Authorized Representative of Assignee

\_\_\_\_\_  
Witness

\_\_\_\_\_  
Witness

=====

ASSIGNMENT

WHEREAS,

1. *Graham Buckton* residing at 24 TAWORTH LANE, FLEET, GUS12W, UK
  2. *Mark Hooper* residing at \_\_\_\_\_
- hereinafter referred to as Assignor(s), have invented a certain invention entitled:

SALT CRYSTALS

for which invention an application (provisional or non-provisional) for a PCT patent was filed on June 21, 2013, under PCT Application No. PCT/US2013/047123, and

WHEREAS, Intra-Cellular Therapies, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware, and having an office and place of business at 3960 Broadway, New York, NY 10032, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Pursuant to the agreement PMSQ1105 with an Issue Date of June 19, 2009; PMS1170 with an Issue Date of August 24, 2009; and PMSQ1225 with an Issue Date of December 10, 2009, between Pharmaterials Limited, having a place of business at Unit B, 5 Boulton Road, Reading, RG2 0NH, United Kingdom, and Intra-Cellular Therapies, Inc., having a place of business at 3960 Broadway, New York, NY 10032, Assignor(s) assign and transfer to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, utility model applications, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, and the patents that may issue thereon,

Assignor(s) convey to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor(s) will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor(s) will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor(s) and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor(s) authorize Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor(s) and Assignee agree that New York State law governs this assignment, and

Assignee acknowledges and accepts this assignment, as evidenced by the signature of an officer or authorized representative of Assignee below.

IN WITNESS WHEREOF, Assignor has hereunto set their hand as indicated below.

This Assignment is effective as of: June 20, 2013

.....  
Assignor *Mark Hooper*

.....  
Witness

.....  
Witness  
.....

*B. Buckton*  
.....  
Assignor *Graham Buckton*

*R. Rowe*  
.....  
Witness

*C. Harney*  
.....

Witness

=====

Receipt acknowledged by Assignee:

-----

Name: ~~Sharon Mates~~ Allen Fienberg  
Title: ~~Chairman and Chief Executive Officer~~ Vice President, Business Development  
of Intra-Cellular Therapies, Inc.

Officer of Authorized Representative of Assignee

-----

Witness

-----

Witness

=====



ASSIGNMENT

WHEREAS,

1. Graham Buckton residing at [REDACTED]
  2. Mark Hooper residing at [REDACTED]
- hereinafter referred to as Assignor(s), have invented a certain invention entitled:

SALT CRYSTALS

for which invention an application (provisional or non-provisional) for a PCT patent was filed on June 21, 2013, under PCT Application No. PCT/US2013/047123, and

WHEREAS, Intra-Cellular Therapies, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware, and having an office and place of business at 3960 Broadway, New York, NY 10032, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Pursuant to the agreement PMSQ1105 with an Issue Date of June 19, 2009; PMS1170 with an Issue Date of August 24, 2009; and PMSQ1225 with an Issue Date of December 10, 2009, between Pharmaterials Limited, having a place of business at Unit B, 5 Boulton Road, Reading, RG2 0NH, United Kingdom, and Intra-Cellular Therapies, Inc., having a place of business at 3960 Broadway, New York, NY 10032, Assignor(s) assign and transfer to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, utility model applications, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, and the patents that may issue thereon,

Assignor(s) convey to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor(s) will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor(s) will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor(s) and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor(s) authorize Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor(s) and Assignee agree that New York State law governs this assignment, and

Assignee acknowledges and accepts this assignment, as evidenced by the signature of an officer or authorized representative of Assignee below.

IN WITNESS WHEREOF, Assignor has hereunto set their hand as indicated below.

This Assignment is effective as of: June 20, 2013

=====  
\_\_\_\_\_  
Assignor *Mark Hooper*

\_\_\_\_\_  
Witness

\_\_\_\_\_  
Witness  
=====

=====  
\_\_\_\_\_  
Assignor *Graham Buckton*

\_\_\_\_\_  
Witness  
\_\_\_\_\_


Witness


=====  
Receipt acknowledged by Assignee:



Name: ~~Sharon Mates~~ ALLEN FIENBERG  
Title: ~~Chairman and Chief Executive Officer~~ VICE PRESIDENT, BUSINESS DEVELOPMENT  
~~of Intra-Cellular Therapies, Inc.~~

Officer of Authorized Representative of Assignee

 17 June 2014  
Witness

 17 Jun 2014  
Witness

ASSIGNMENT

WHEREAS,

1. *Peng Li* having an address at *3960 Broadway, New York, NY 10032*
  2. *Lawrence P. Wennogle* having an address at *3960 Broadway, New York, NY 10032*
  3. *Robert Davis* having an address at *3960 Broadway, New York, NY 10032*
- hereinafter referred to as Assignor(s), have invented a certain invention entitled:

SALT CRYSTALS

for which invention an application (provisional or non-provisional) for a PCT patent was filed on *June 21, 2013*, under PCT Application No. *PCT/US2013/047123*, and

WHEREAS, Intra-Cellular Therapies, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware, and having an office and place of business at 3960 Broadway, New York, NY 10032, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor(s) assign and transfer to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, utility model applications, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, and the patents that may issue thereon,

Assignor(s) convey to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor(s) will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor(s) will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue

the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor(s) and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor(s) authorize Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor(s) and Assignee agree that New York State law governs this assignment, and

Assignee acknowledges and accepts this assignment, as evidenced by the signature of an officer or authorized representative of Assignee below.

IN WITNESS WHEREOF, Assignor has hereunto set their hand on the dates indicated below.

This Assignment is effective as of: June 20, 2013

=====  
*Peng Li* 06/17/2014  
Assignor Peng Li

*Joseph Kardiel* 17 Jun 2014  
Witness

*Gordon Bryan* 17 June 2014  
Witness

=====  
*L. W. Wenig* 06-17-2014  
Assignor Lawrence P. Wenig

*Joseph Kardiel* 17 Jun 2014  
Witness


*Gordon Bryan* 17 June 2014  
Witness

=====  
Assignor Robert Davis

Witness \_\_\_\_\_

Witness \_\_\_\_\_

=====  
Receipt acknowledged by Assignee:




Name: Sharon Mates ALLEN FIENBERG

Title: Chairman and Chief Executive Officer  
of Intra-Cellular Therapies, Inc.

VICE PRESIDENT, BUSINESS DEVELOPMENT

Officer of Authorized Representative of Assignee

  
Witness 17 June 2014

  
Witness 17 Jun 2014

ASSIGNMENT

WHEREAS,

1. *Peng Li* having an address at *3960 Broadway, New York, NY 10032*
  2. *Lawrence P. Wennogle* having an address at *3960 Broadway, New York, NY 10032*
  3. *Robert Davis* having an address at *3960 Broadway, New York, NY 10032*
- hereinafter referred to as Assignor(s), have invented a certain invention entitled:

SALT CRYSTALS

for which invention an application (provisional or non-provisional) for a PCT patent was filed on *June 21, 2013*, under PCT Application No. *PCT/US2013/047123*, and

WHEREAS, Intra-Cellular Therapies, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware, and having an office and place of business at 3960 Broadway, New York, NY 10032, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor(s) assign and transfer to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, utility model applications, substitution, registration, renewal, extension, Supplementary Protection Certificates or the like) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, and the patents that may issue thereon,

Assignor(s) convey to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor(s) will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor(s) will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue

the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor(s) and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor(s) authorize Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor(s) and Assignee agree that New York State law governs this assignment, and

Assignee acknowledges and accepts this assignment, as evidenced by the signature of an officer or authorized representative of Assignee below.

IN WITNESS WHEREOF, Assignor has hereunto set their hand on the dates indicated below.

This Assignment is effective as of: June 20, 2013

=====  
\_\_\_\_\_  
Assignor *Peng Li*

\_\_\_\_\_  
Witness

\_\_\_\_\_  
Witness

=====  
\_\_\_\_\_  
Assignor *Lawrence P. Wennogle*

\_\_\_\_\_  
Witness

\_\_\_\_\_  
Witness



*Robert Lewis*

Assignor

Witness

Witness

Receipt acknowledged by Assignee:

Name:

Title:

Officer of Authorized Representative of Assignee

Witness

Witness